Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2446 to 2460 of 7683 results

  1. Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

    In development [GID-TA11233] Expected publication date: 04 June 2025

    Technology appraisal guidance
    In development

  2. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment

    In development [GID-HTE10041] Expected publication date: 22 May 2025

    Health technology evaluations
    In development

  5. Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459

    In development [GID-TA11572] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: 18 June 2025

    Technology appraisal guidance
    In development

  7. Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Iptacopan for treating complement 3 glomerulopathy ID6283

    In development [GID-TA11331] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 November 2024.

    Technology appraisal guidance
    In consultation

  11. Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

    In development [GID-TA10653] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Prolonged-release diazoxide choline for treating Prader-Willi syndrome [ID1389]

      Status ...

    Technology appraisal guidance
    Topic selection

  13. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442

    In development [GID-TA11424] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

    In development [GID-TA11431] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development